Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing prevalence of antibiotic-resistant infections
3.2.1.2 High R&D investments in clinical research
3.2.1.3 Growing incidence of hospital-acquired infections
3.2.1.4 Increased awareness and diagnostic advancements
3.2.2 Industry pitfalls & challenges
3.2.2.1 High cost of production of carbapenem-based antibiotics
3.2.2.2 Side effects and safety concerns
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Technological landscape
3.5.1 Core technologies
3.5.2 Adjacent technologies
3.6 Pricing analysis, 2023
3.6.1 By region
3.6.2 By key player
3.7 Future market trends
3.8 Porter’s analysis
3.9 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Drug Class, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Meropenem
5.3 Imipenem
5.4 Ertapenem
5.5 Doripenem
5.6 Other drug classes
Chapter 6 Market Estimates and Forecast, By Application, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Urinary tract infections
6.3 Bloodstream infections
6.4 Intra-abdominal infections
6.5 Bacterial meningitis
6.6 Other applications
Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Hospital pharmacies
7.3 Retail pharmacies
7.4 Online pharmacies
Chapter 8 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 North America
8.2.1 U.S.
8.2.2 Canada
8.3 Europe
8.3.1 Germany
8.3.2 UK
8.3.3 France
8.3.4 Spain
8.3.5 Italy
8.3.6 Netherlands
8.3.7 Rest of Europe
8.4 Asia Pacific
8.4.1 China
8.4.2 Japan
8.4.3 India
8.4.4 Australia
8.4.5 South Korea
8.4.6 Rest of Asia Pacific
8.5 Latin America
8.5.1 Brazil
8.5.2 Mexico
8.5.3 Argentina
8.5.4 Rest of Latin America
8.6 Middle East and Africa
8.6.1 South Africa
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Rest of Middle East and Africa
Chapter 9 Company Profiles
9.1 AstraZeneca PLC
9.2 Aurobindo Pharma
9.3 Daewoong Pharmaceuticals Co., Ltd.
9.4 F. Hoffmann-La Roche Ltd.
9.5 Johnson & Johnson
9.6 Kopran Limited
9.7 Lupin Limited
9.8 Merck & Co., Inc.
9.9 Novartis AG
9.10 Pfizer Inc.
9.11 Shenzhen Haibin Pharmaceutical Co. Ltd.
9.12 Sun Pharmaceutical Industries Ltd.
9.13 The Menarini Group
9.14 Venus Remedies Ltd.
9.15 Viatris Inc.
